trending Market Intelligence /marketintelligence/en/news-insights/trending/yytscb31oe63nxffalez8a2 content esgSubNav
In This List

Akari Therapeutics gets Nasdaq noncompliance notice

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Akari Therapeutics gets Nasdaq noncompliance notice

Akari Therapeutics PLC said it fell out of compliance with a Nasdaq listing requirement after failing to file its annual report for the year ended Dec. 31, 2017, on time.

The biopharmaceutical company has until Nov. 12 to regain compliance.

Akari's CEO recently resigned following an internal investigation that revealed he used the company's credit card for personal use.

Akari said it found David Solomon violating the drugmaker's policies after incurring personal charges on the company's corporate credit cards.